Patisiran Sodium Patent Expiration
Patisiran Sodium is Used for treating hereditary transthyretin-mediated amyloidosis polyneuropathy. It was first introduced by Alnylam Pharmaceuticals Inc
Patisiran Sodium Patents
Given below is the list of patents protecting Patisiran Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Onpattro | US10240152 | Compositions and methods for inhibiting expression of transthyretin | Oct 20, 2029 | Alnylam Pharms Inc |
| Onpattro | US11079379 | Methods of treating transthyretin (TTR) mediated amyloidosis | Aug 27, 2035 | Alnylam Pharms Inc |
| Onpattro | US11141378 | Lipid formulations for nucleic acid delivery | Apr 15, 2029 | Alnylam Pharms Inc |
| Onpattro | US8058069 | Lipid formulations for nucleic acid delivery | Apr 15, 2029 | Alnylam Pharms Inc |
| Onpattro | US8158601 | Lipid formulation | Nov 10, 2030 | Alnylam Pharms Inc |
| Onpattro | US8168775 | Compositions and methods for inhibiting expression of transthyretin | Oct 20, 2029 | Alnylam Pharms Inc |
| Onpattro | US8334373 | Nuclease resistant double-stranded ribonucleic acid | May 27, 2025 | Alnylam Pharms Inc |
| Onpattro | US8362231 | RNA interference mediating small RNA molecules |
Mar 30, 2021
(Expired) | Alnylam Pharms Inc |
| Onpattro | US8372968 | RNA interference mediating small RNA molecules |
Mar 30, 2021
(Expired) | Alnylam Pharms Inc |
| Onpattro | US8492359 | Lipid formulations for nucleic acid delivery | Apr 15, 2029 | Alnylam Pharms Inc |
| Onpattro | US8552171 | RNA sequence-specific mediators of RNA interference |
Mar 30, 2021
(Expired) | Alnylam Pharms Inc |
| Onpattro | US8642076 | Lipid containing formulations | Oct 03, 2027 | Alnylam Pharms Inc |
| Onpattro | US8741866 | Compositions and methods for inhibiting expression of transthyretin | Oct 20, 2029 | Alnylam Pharms Inc |
| Onpattro | US8778902 | RNA interference mediating small RNA molecules |
Mar 30, 2021
(Expired) | Alnylam Pharms Inc |
| Onpattro | US8802644 | Lipid formulation | Oct 21, 2030 | Alnylam Pharms Inc |
| Onpattro | US8822668 | Lipid formulations for nucleic acid delivery | Apr 15, 2029 | Alnylam Pharms Inc |
| Onpattro | US8895718 | RNA interference mediating small RNA molecules |
Mar 30, 2021
(Expired) | Alnylam Pharms Inc |
| Onpattro | US8895721 | RNA interference mediating small RNA molecules |
Mar 30, 2021
(Expired) | Alnylam Pharms Inc |
| Onpattro | US9193753 | RNA sequence-specific mediators of RNA interference |
Mar 30, 2021
(Expired) | Alnylam Pharms Inc |
| Onpattro | US9234196 | Compositions and methods for inhibiting expression of transthyretin | Oct 20, 2029 | Alnylam Pharms Inc |
| Onpattro | US9364435 | Lipid formulations for nucleic acid delivery | Apr 15, 2029 | Alnylam Pharms Inc |
| Onpattro | US9567582 | RNA interference mediating small RNA molecules |
Mar 30, 2021
(Expired) | Alnylam Pharms Inc |
| Onpattro | US9943538 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov 04, 2023
(Expired) | Alnylam Pharms Inc |
| Onpattro | US9943539 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov 04, 2023
(Expired) | Alnylam Pharms Inc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳